Ipilimumab

Ipilimumab · Immune Checkpoint Inhibitor (PD-1 / PD-L1 / CTLA-4)

Back to Cancer Drug Encyclopedia Find Recruiting Trials with this Drug →

Indications & Uses

Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Urothelial Cancer, Head and Neck Cancer, MSI-H/dMMR solid tumors, and Cervical Cancer.

Contraindications

History of severe life-threatening immune-mediated adverse reaction to prior checkpoint inhibitor.

Side Effects & Warnings

Immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, nephritis, endocrinopathies, rash), fatigue, pruritus.

Drug & Dietary Interactions

Caution with strong CYP3A inhibitors or inducers; review concurrent medications.

For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.

Patient & Caregiver Support

Ask About This Medication

Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.